Mizuho Securities Reaffirms Their Buy Rating on Gilead Sciences (GILD)
September 12 2022 - 09:45AM
TipRanks
In a report released today, Salim Syed from Mizuho Securities
maintained a Buy rating on Gilead Sciences (GILD - Research
Report), with a price target of $75.00. The company's shares opened
today at $68.07.Syed covers the Healthcare sector, focusing on
stocks such as Cytokinetics, Atara Biotherapeutics, and Coherus
Biosciences. According to TipRanks, Syed has an average return of
-13.1% and a 39.78% success rate on recommended stocks. Gilead
Sciences has an analyst consensus of Moderate Buy, with a price
target consensus of $70.85, implying a 4.08% upside from current
levels. In a report released today, RBC Capital also maintained a
Buy rating on the stock with a $79.00 price target.
https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-gilead-sciences-gild?utm_source=advfn.com&utm_medium=referral
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Dec 2022 to Jan 2023
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jan 2022 to Jan 2023